
Life Sciences
- Overview
- Who To Contact
- Representative Matters
- Recent Developments
Canada’s life sciences sector is fast-moving and globally driven, shaped by scientific breakthroughs, shifting regulations and rising demand for innovation. The Aird & Berlis and Aird & McBurney Life Sciences Group blends legal expertise with scientific insight to help startups, scaleups and industry leaders protect their ideas, attract investment and drive sustainable growth.
Our team’s specialized knowledge and experience equip us with a deep understanding of the legal and intellectual property considerations that are unique to clients operating in this space. Many of our multidisciplinary professionals hold doctoral, master’s and engineering degrees in biochemistry, pharmacology, chemistry, biology, medical sciences, infection and immunity, physics, math and related fields.
We provide clients with counsel on the issues facing life sciences businesses, including regulations, mergers and acquisitions, financing, capital markets, licencing, commercial agreements, intellectual property, labour and employment, privacy, confidentiality, litigation and dispute resolution, and tax in Canada.
We support our clients in developing global intellectual property strategies, including the drafting, filing and defence of patent applications. Our team also brings extensive knowledge and experience to address ever-evolving technological advancements that demand a combination of life sciences expertise and proficiency in AI and other computer-related fields.
Our team represents a wide range of clients, including life science, pharmaceutical, health science, veterinary, agricultural, food and beverage, cosmetic, natural health product, medical device, technology and biotechnology companies, as well as hospitals, universities and research institutions.
We bring extensive capital markets expertise that spans both domestic and cross-border matters. We help clients accelerate growth through financing and go-public transactions, including initial public offerings, reverse takeovers and qualifying transactions, as well as listings on the Canadian Securities Exchange, TSX, TSXV and Cboe Canada Exchange. We also draw from our comprehensive legal, intellectual property and regulatory knowledge to advise companies, investors, lenders and other market participants pursuing opportunities in the life sciences sector.
- Pharmaceuticals: We help clients succeed in Canada’s highly regulated and fast-changing pharmaceutical sector, including inventors, developers, hospitals, universities, research institutions and Fortune 100 companies. Our lawyers and patent agents have extensive experience in pharmaceutical patent prosecution, portfolio management and litigation, including infringement and validity actions, and proceedings under the Patented Medicines (Notice of Compliance) Regulations.
- Medical Devices: We support medical device companies throughout the product lifecycle, working with inventors, manufacturers, developers, licensors, distributors, hospitals, investors and other stakeholders. Our work spans imaging and image-guided therapies, diagnostics, minimally invasive technologies, targeted drug delivery systems, surgical tools, assays, wound dressings, prosthetics and digital health and AI. We regularly advise on Health Canada product regulations and licensing requirements related to manufacturing and market access. We also provide guidance on intellectual property strategy and portfolio development, as well as the assertion and defence of intellectual property rights.
- Psychedelics: Aird & Berlis and Aird & McBurney are recognized leaders in the psychedelics industry, advising private and public companies focused on pharmaceutical development, nutraceuticals and clinical operations. We remain at the forefront of the legal, intellectual property, regulatory and investment shifts taking place in Canada, the United States and globally, continuing the leadership we established during the rise of Canada’s cannabis industry. Our team guides clients through international and domestic regulations, including the Controlled Drugs and Substances Act, Criminal Code, Health Canada Act and Food and Drugs Act. As a full-service firm, we collaborate across practice areas to meet the full range of legal and patent needs in this space.
- Food and Beverage Products: We advise food and beverage companies on all aspects of their operations, with a focus on regulatory compliance and food safety. We assist with matters involving the Canadian Food and Drugs Act and the Canadian Food Inspection Agency, including import and export requirements, licencing, inspections and product recalls. We also advise on intellectual property strategy and portfolio development, as well as the assertion and defence of intellectual property rights.
- Other Notable Areas: Our life sciences expertise also includes agriculture and plant science, biology, biotechnology, biochemistry, chemistry, diagnostics, genomics, green technologies, immunology, nanotechnology, therapeutics, veterinary and virology.
Contacts
-
BioFull bio
Sherri earns the trust of her clients by adeptly managing complex and time-sensitive corporate finance transactions and by providing relevant, busines...
-
BioFull bio
Richard is a creative and results-driven corporate finance lawyer. Both domestically and internationally, Richard brings his business knowledge to th...
-
BioFull bio
With extensive experience in a broad range of corporate finance and commercial matters, Jeffrey offers clients a practical and business-minded approac...
Group Members
Representative Matters
-
Willow Biosciences Completes Brokered Private Placement
Aird & Berlis represented Independent Trading Group (ITG) Inc., as lead agent and sole bookrunner, in Willow Biosciences Inc.’s brokered private placement of units. -
Cybin Completes US$150-Million Private Placement of Common Shares
On March 19, 2024, Cybin Inc. completed a US$150-million private placement of common shares. -
Phillips Foods Acquires Assets of Canadian Seafood Processor and Distributor
On March 7, 2024, Phillips Foods Inc., a U.S.-based global processor and distributor of branded seafood products, announced that it will acquire the assets of South Shore Seafoods Group of Companies, ... -
Cybin Announces Completion of Underwritten Public Offering of Units
On November 14, 2023, Cybin Inc. (NEO:CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedel... -
CanAm Scientific Partnership With Dubai Hospital Set to Transform Men’s Health in the UAE
CanAm Scientific, a global leader in technology, supply and manufacturing, has signed an exclusive agreement with Clemenceau Medical Center Hospital in Dubai to establish the hospital as the first med... -
Cybin Inc. Completes Acquisition of Small Pharma Inc.
On October 23, 2023, Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) and Small Pharma Inc. (TSXV: DMT) announced the completion of Cybin's acquisition of all of Small Pharma's issued and outstanding secu... -
Cybin Announces At-the-Market Equity Program of Up to US$35 Million
On August 23, 2023, Cybin Inc. announced the renewal of its previously established at-the-market equity program that allows Cybin to issue and sell up to US$35 million of common shares from treasury t... -
Cybin Completes Overnight Marketed Public Offering of Units
On August 4, 2023, Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) announced the closing of its previously announced overnight marketed public offering. -
Cybin Enters US$30-Million Common Share Purchase Agreement
On May 30, 2023, Cybin Inc. entered into a common share purchase agreement with Lincoln Park Capital Fund, LLC, an institutional investor. -
Juno Pharmaceuticals Acquires Omega Laboratories
Juno Pharmaceuticals Corp., a leader in the commercialization of specialty pharmaceutical products, announced its acquisition of Omega Laboratories.
Recent Developments
-
Firm News
Timothy Lowman and Kimberly McManus Recognized in 2025 LMG Life Sciences Guide
We are proud to share that Timothy Lowman and Kimberly McManus, Co-Heads of the firm's Intellectual Property Group, have been recognized as leading practitioners in the 2025 LMG Life Sciences guide. A... -
Firm News
117 Aird & Berlis Lawyers Recognized in The Best Lawyers in Canada 2026
Aird & Berlis is proud to announce that 117 members of the firm were selected by their peers for inclusion in the 2026 edition of The Best Lawyers in Canada. We are also pleased to share that an addit... -
TheSpotlight
Patents and Prior Art: Federal Court Clarifies Standards for Anticipation and Obviousness
This article analyzes a recent Federal Court decision, which clarifies the high threshold for using prior art to establish anticipation and obviousness in patent validity challenges, particularly in t... -
TheSpotlight
Important New Procedural Guidelines From the PMPRB
On June 30, 2025, the Patented Medicine Prices Review Board released new Guidelines to monitor and review drug prices in Canada. The new Guidelines will take effect on January 1, 2026. -
Article
Closing the Value Gap Using Earnouts in Life Sciences M&A
This article examines how earnouts help bridge valuation gaps in life sciences M&A, highlighting their widespread use, industry-specific complexities and the need for careful structuring to manage ris... -
Firm News
Aird & Berlis Lawyers Featured in Global Top 200 Psychedelic Lawyers Directory 2025
Sherri Altshuler, Danny Kharazmi, Jeffrey Merk, and Russell Sanders have once again been recognized for their industry expertise. -
TheSpotlight
PMPRB’s Jurisdiction Limited to Patented Medicines
This article discusses the Federal Court of Appeal's decision in Galderma Canada Inc v. Canada (Attorney General), which clarified that the Patented Medicine Prices Review Board's jurisdiction is limi... -
Article
B.C. Cost Recovery Legislation Has Significant Implications for Product and Service Providers
The Government of British Columbia has announced its intention to facilitate civil suits by provincial and federal governments seeking cost recovery, on an unprecedented scale, for “health-related wro... -
TheSpotlight
Abuse of Process: Federal Court of Appeal Clarifies Application in PM(NOC) Proceedings
In the recent decision of Janssen Inc. v. Apotex Inc., the Canadian Federal Court of Appeal declared a subsequent action brought under the Patented Medicines (Notice of Compliance) Regulations to be a... -
Firm News
Aird & Berlis Lawyers Recognized in Global Top 200 Psychedelic Lawyers Directory 2024
The following members of our Life Sciences Group were recognized: Sherri Altshuler, Melanie Cole, Sean Green, Danny Kharazmi, Richard Kimel, Jeffrey Merk and Russell Sanders. -
Firm News
Aird & Berlis Welcomes Nine New Partners
Aird & Berlis is pleased to announce that Meaghan Barrett, Jacob Brown, Holly Cunliffe, Alex Kagan, Amy Marcen-Gaudaur, Dasha Peregoudova, Stefan Radovanovich, Russell Sanders and Leah Silber have bec... -
Event
Psychedelics: A Complex and Changing Regulatory Landscape Focused on Scientific Research and IP Protection
- 04:00 PMJoin our panel of industry experts for a complimentary webinar to learn about recent scientific research on psychedelic medicine, updates to the shifting regulatory landscape, and how to navigate the ... -
TheSpotlight
Whose Liability Is It Anyway? The Court Clarifies the Burden in Summary Trials and Infers Inducement
In Janssen Inc. v. Pharmascience Inc., 2022 FC 62, the Federal Court highlighted two important issues: the burden in summary trial proceedings and the evidentiary burden for proving inducement of pate... -
Article
New Tier, New Horizons for the Canadian Securities Exchange
In order to continue to evolve with developments in the Canadian capital markets, particularly with many more established companies choosing the CSE as their preferred Canadian stock exchange, the CSE...